Global Biotinidase Deficiency Market, By Category (Profound and Partial), Consumers (Men, Women, Kids), Application (Skincare, Haircare, Nail Care, Others), Dosage Form (Capsules, Tablets, Powder, Soft Gels, Liquid, Others), Purpose (Beauty and Energy), Source (Vegetable and Meat), End-Users (Clinics, Hospitals, Drug Stores, Retail Pharmacy, Online Pharmacy), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Biotinidase deficiency market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 3.80% in the above-mentioned research forecast period. Increased awareness among people towards aesthetic treatment and increasing prevalence of genetic disorder couple with growing awareness of alternative multivitamin and biotin supplement among others.
Increasing adoption of medicines that can prevent the body from biotin absorption and advancement in sources of biotin supplement also boost up the market growth. Moreover increasing research and development and rising healthcare expenditure act as an opportunity for the market growth. But, side effects associated with treatment options and strict regulatory framework among other may hamper the global biotinidase deficiency market.
Biotinidase deficiency is characterized as an autosomal recessive disorder in which an affected individual lacks the ability to recycle biotin and vitamin in the body. Biotinidase deficiency is caused due to the mutation in the BTD gene. It results in the accumulation of alanine and lactic acid in the body. Profound biotinidase includes less than 10% of normal serum enzyme activity and patients who have been reported with 10-30% of mean normal serum activity have partial biotinidase deficiency. As it leads to immunologic dysfunction, the affected individuals are more prone to recurrent fungal and viral infections. Moreover, affected children also experience neurological and cutaneous problems. The most common neurological symptoms include hypotonia and seizures. Skin rash and hair loss also develop among the affected individuals. Biotinidase deficiency can be detected by measuring the biotinidase activity in serum, plasma, fibroblasts, and leukocytes. Genetic analysis detecting BD gene and new born screening can also be used for detection of biotinidase deficiency. Biotin therapy is highly recommended for the treatment of biotinidase deficiency.
The patients suffering from biotinidase deficiency is increasing worldwide, with a reported 1 in every 40,000 to 1 in every 60,000 people. Moreover, in developing countries, the prevalence rate is much higher. This patient population is largely dependent upon advanced treatment options and hence expected to provide the market with lucrative growth. It is also estimated that the biotinidase deficiency market was growing with a CAGR of 3.80% in 2020.
This biotinidase deficiency market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Biotinidase deficiency Market Scope and Market Size
Biotinidase deficiency market is segmented on the basis of category, consumers, application, dosage form, purpose, source, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of category, the biotinidase deficiency market is segmented into profound and partial.
- On the basis of consumers, the biotinidase deficiency market is segmented into men, women and kids.
- On the basis of application, the biotinidase deficiency market is segmented into skincare, haircare, nail care and others.
- On the basis of dosage form, the biotinidase deficiency market is segmented into capsules, tablets, powder, soft gels, liquid and others.
- On the basis of purpose, the biotinidase deficiency market is segmented into beauty and energy.
- On the basis of source, the biotinidase deficiency market is segmented into vegetable and meat.
- On the basis of end-users, the biotinidase deficiency market is segmented into clinics, hospitals, drug stores, retail pharmacy and online pharmacy.
- On the basis of distribution channel, the biotinidase deficiency market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy, others.
Biotinidase Deficiency Market Country Level Analysis
Biotinidase deficiency market is analysed and market size information is provided by country, category, consumers, application, dosage form, purpose, source, end-users and distribution channel as referenced above.
The countries covered in the biotinidase deficiency market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts for the largest market share due to the increasing prevalence of biotinidase deficiency and increasing research and development activities. Europe is also expected to grow due to increasing diagnostic rates, including newborn screening among others and expanding product distribution network. Asia-Pacific is growing at fastest pace due to rising government initiatives for boosting the growth of pharmaceutical sector.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Biotinidase deficiency market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Biotinidase Deficiency Market Share Analysis
Biotinidase deficiency market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to biotinidase deficiency market.
The major players covered in the biotinidase deficiency market are Life Garden Naturals, Zhou Nutrition, SBRNUTRITION, Natrol LLC, Church & Dwight Co., Inc., Zenwise, TRIVITRON HEALTHCARE PVT. LTD., Mericon Industries, Inc ., NTD Genetics, PerkinElmer Inc., Garden of Life, Pure Encapsulations, LLC., KLAIRE LABS, NUTRA HEALTHCARE, DSM, BIOVENCER HEALTHCARE PRIVATE LIMITED, Merck KGaA, Biogena, Avalon Organics, Aanstar Technologies Pvt Ltd. among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.